Orlando, Fla.—A scoring system specifically designed to predict relapse and overall survival (OS) in patients with myelodysplastic syndrome (MDS) undergoing an allogeneic hematopoietic cell transplant (allo-HCT) appears viable and may be a useful management tool.
Compared with the Revised International Prognostic Scoring System (IPSS-R) for MDS, the tool was associated with greater accuracy for several outcomes, including OS in patients who underwent human leukocyte antigen